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THE INFLUENCE OF PARENTERAL NUTRITION ON THE PLASMA 
PROTEIN BINDING OF THERAPEUTIC DRUGS
Salih M, Bahari MB, Abd AY, Shaﬁ e AA
Universiti Sains Malaysia, Minden, Penang, Malaysia
OBJECTIVES: Parenteral nutrition (PN) is used in various clinical situations. 
However, some interactions might occur with drugs that are administered concur-
rently with PN. Therefore, this search reviews the potential interactions of PN with 
therapeutic drugs (mainly antiepileptics), especially in respect to the plasma protein-
binding of the drug. METHODS: The articles related to the topic were identiﬁ ed 
through the Medline and PubMed. Full text of the articles were then traced from the 
Universiti Sains Malaysia (USM) library subscribed databases, including Wiley-Black-
well Library, Cochrane Library, EBSCOHost, OVID, ScienceDirect, SAGE Premier, 
Scopus, SpringerLINK, and Wiley InterScience. The articles from journals not listed 
by USM library were traced through inter library loan. RESULTS: There were interac-
tions between PN and drugs, including antiepileptics. Several guidelines were designed 
for the management of illnesses such as traumatic brain injuries or cancer patients, 
involving the use of PN and antiepileptics. Moreover, many studies demonstrated the 
in vitro and in vivo PN-drugs interactions, especially with antiepileptics. CONCLU-
SIONS: Alteration in the drug-free fraction result from PN-drug (i.e. antiepileptics) 
interactions may necessitate scrupulous reassessment of drug dosages in patients 
receiving these therapies. This reassessment may be particularly imperative in certain 
clinical situations characterized by hypoalbuminemia (e.g., burn patients).
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EFFICACY AND TOLERABILITY OF INTERFERON-BETA IN ALL TYPE OF 
MULTIPLE SCLEROSIS
Nikfar S1, Abdollahi M2, Rahimi R3
1Faculty of Pharmacy, Tehran University of Medical Sciences and Food & Drug Laboratory 
Research Center, MOH, Tehran, Iran; 2Faculty of Pharmacy; and Pharmaceutical Sciences 
Research Center, Tehran University of Medical Sciences, Tehran, Iran; 3Faculty of Traditional 
Medicine, and Pharmaceutical Sciences Research Center, Tehran University of Medical 
Sciences, Tehran, Iran
OBJECTIVES: The aim of this meta-analysis was to evaluate the efﬁ cacy and tolerabil-
ity of IFN β for maintenance of remission in MS. METHODS: Pubmed, Scopus, and 
Cochrane Central Register of Controlled Trials were searched for studies investigated 
efﬁ cacy and/or tolerability of interferon β (IFN β) in MS. Data were collected from 
1966 to 2009 (up to July). RESULTS: Nine randomized placebo controlled clinical 
trials met our criteria and were included. Summary relative risk (RR) for at least one 
relapse including all types of MS and all types of IFN β was 0.86, a signiﬁ cant RR 
(95% CI: 0.76–0.97). Summary RR for at least one relapse in secondary progressive 
MS (SPMS) patients received all types of IFN β was 1.11(95% CI: 0.79–1.55). RR 
for at least one relapse in RRMS patients received all types of IFN β was 0.77(95% 
CI: 0.57–1.05). RR for at least one relapse in SPMS patients received IFN β-1b was 
0.93 (95% CI: 0.75–1.14). RR for at least one relapse in patients with all types of 
MS received IFN β-1a was 0.97 (95% CI: 0.57–1.67) and for IFN β-1b was 0.92 
(95% CI: 0.85–1). The summary RR for discontinuing because of adverse events in 
nine trials was 2.76, a non-signiﬁ cant RR (95% CI: 1.97–3.89, P < 0.0001). The 
summary RR death in three trials was 1.53 (95% CI: 0.45–5.15). RR for suicides or 
suicide attempts in ﬁ ve trials was 0.86 (95% CI: 0.41–1.79). RR for different adverse 
events of all types of IFN β comparing to placebo in all types of MS including ﬂ u-like 
symptoms, injection site reactions, injection site inﬂ ammation, myalgia, leucopenia, 
lymphopenia, increased alanine aminotransferase were signiﬁ cant except for depres-
sion that its RR was non-signiﬁ cant. CONCLUSIONS: It can be concluded that INF 
β’s effectiveness in MS is dependent to administration of different kind of interferon 
β and type of MS. 
NEUROLOGICAL DISORDERS – Cost Studies
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BUDGET IMPACT ANALYSIS OF NATALIZUMAB FOR MULTIPLE 
SCLEROSIS TREATMENT IN BRAZIL: A 5-YEAR PROJECTION
Ferreira Da Silva AL1, Finkelsztejn A1, Ribeiro R2, Polanczyk CA1
1Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; 2Hospital de Clínicas 
de Porto Alegre, Porto Alegre, Brazil
OBJECTIVES: To estimate the annual and 5-year budgetary impact of including 
natalizumab in the Brazilian public health care system drug formulary for the treat-
ment of relapsing remitting multiple sclerosis (MS). METHODS: Brazilian public 
health care system perspective was adopted. The baseline scenario comprised four 
treatment options available in Brazil in the year 2009, and its corresponding market 
shares: 1) interferon beta 1A intramuscular (23%); 2) interferon beta 1A subcutaneous 
(32%); 3) interferon beta 1B (23%); and (4) glatiramer acetate (22%). Data were 
retrieved from the Brazilian health system database. a claims data based approach was 
used to estimate the baseline population size, which was estimated to be 6935 patients. 
In addition to the base-case scenario, three alternative scenarios were created to 
estimate the budgetary impact of including natalizumab to the drug formulary at 3 
possible market shares: 3%, 10% or 22%. Costs for currently available treatments 
comprised average purchase prices paid by the Brazilian government in 2009. The 
adopted natalizumab dose cost was R$,652 (c1660), obtained from public data issued 
by the Brazilian’s regulatory health agency (ANVISA). Costs were adjusted for 4% 
annual inﬂ ation. No discounts were considered. Sensitivity analysis was performed. 
RESULTS: Base-case costs for treatment of MS within a 5-year period were 
R$1280,698,041 (c582,135,473). Relative to this value, at 3% market share, the 
inclusion of natalizumab produced a 6% (R$78,858,437/c35,844,744) increase in 
expenditures. At 10% market share, the corresponding expenditures increased 9% 
(R$108,902,983/c49,501,356). At 22% market share, there was an increase of 13% 
in total costs with MS treatment (R$161,903,806/c73,592,639). CONCLUSIONS: 
Entry of natalizumab into the market is likely to result in a signiﬁ cant increase in MS 
treatment costs for the Brazilian health care system. However, this must be weighted 
against the need for new treatment options as well as potential savings from better 
disease control rates.
PND5
BUDGET-IMPACT MODEL TO TEST EFFECTS OF CHANGING 
RUFINAMIDE TIER STATUS FROM A PAYER PERSPECTIVE
Powers A1, Faria C1, Buchner D1, Shaul A2, Cragin L3
1Eisai, Inc., Woodcliff Lake, NJ, USA; 2United BioSource Corporation, Bethesda, MD, USA; 
3United BioSource Corporation, Lexington, MA, USA
OBJECTIVES: Lennox-Gastaut Syndrome (LGS) is an epileptic encephalopathy char-
acterized by intractable seizures of many types. LGS has its onset in early childhood, 
and often persists into adulthood. It is estimated that the prevalence of LGS among 
children and adults with epilepsy is 6.5% and 1.5%, respectively. This budget impact 
model was developed to help US payers make informed decisions regarding the addi-
tion of ruﬁ namide for the management of LGS. To analyze overall budget impact of 
changing ruﬁ namide from tier 3 to tier 2 status for a large U.S. payer. METHODS: 
The budget impact model was constructed based upon the indicated population for 
ruﬁ namide, which is children 4 years and older and adults (18+) requiring adjunctive 
treatment of seizures associated with LGS. The model follows patients over three years 
and estimates the direct health care costs associated with LGS treatment before and 
after the introduction of ruﬁ namide. The three main categories of data inputs inform-
ing the model include: plan population inputs, treated prevalence inputs, and treat-
ment and cost inputs. The base-case model results are based on data derived from 
published literature, publicly available data sources, or assumptions. The results are 
presented as follows: total costs over 3 years, cost per member per year (PMPY), cost 
per treated member per year (PTMPY), cost per member per month (PMPM), and 
cost per treated member per month (PTMPM). RESULTS: Assuming a one million 
member plan and a discount rate of 3% shifting ruﬁ namide from tier 3 to tier 2 
resulted in $1,001 in additional total costs over 3 years. This translates to a change 
in a PTMPY of $1.00 and a PTMPM of $0.13. PMPY and PMPM were not notably 
affected. CONCLUSIONS: Based on this analysis changing ruﬁ namide from tier 3 to 
tier 2 does not exhibit a signiﬁ cant cost increase.
PND6
VALUE OF BUDGET IMPACT ANALYSIS BASED ON EPIDEMIOLOGIC 
DATA: INSIGHTS FROM MULTIPLE SCLEROSIS IN SAO PAULO, BRAZIL
Ferreira Da Silva AL1, Filkelsztejn A1, Ribeiro R2, Polanczyk CA1
1Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; 2Hospital de Clínicas 
de Porto Alegre, Porto Alegre, Brazil
BACKGROUND: Despite its relatively low prevalence in Brazil, multiple sclerosis (MS) 
is responsible for signiﬁ cant health care expenditures for the public health care system. 
OBJECTIVES: To compare actual MS treatment expenditures and expected expenditures 
based on an epidemiological projection. METHODS: We retrieved actual treated preva-
lence and treatment costs from Brazil’s public health system database for the city of Sao 
Paulo, in 2009. Then, current prevalence of MS for the city of Sao Paulo was estimated 
based on the best epidemiological evidence available, a prevalence study conducted in 
1997, which reported a prevalence of 15/100,000 inhabitants. Data were analyzed com-
paring actual and potential expenditure related to drug treatments, assuming that 85% 
of prevalent cases comprised the relapsing form of MS. RESULTS: We retrieved the total 
number of doses for each one of the available treatment options for MS in the city of São 
Paulo for the year 2009 (interferon beta-1A, interferon beta-1B and glatiramer acetate). 
Considering the expected number of doses required to treat one patient for one year with 
each treatment option, we estimated the number of patients covered within one year of 
treatment to be 1,319 patients. This corresponds to an estimated treated prevalence of 
11.9 cases per 100,000 inhabitants, considering the estimated population for the year 
2009 (11,037,593 inhabitants). Actual costs incurred for the city of Sao Paulo in 2009 
with the treatment of MS were R$40,993,666/c18,633,484. Assuming a prevalence of 
15/100,000 inhabitants, 1,666 cases of MS would be expected in the city, of which 1,416 
would be relapsing MS. Their treatment would require R$43,811,800/c19,914,454. 
CONCLUSIONS: There are marginal differences between treated and expected prevalence 
of relapsing MS in the city of Sao Paulo. This indicates that local programs for MS 
diagnosis and treatment are successful. Likewise, current budget impacted analyses based 
on epidemiologic information seems accurate.  
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ECONOMIC IMPACT OF PERSISTENCE TO DISEASE MODIFYING 
THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Szkurhan AR1, Dembek C2, Malik S1, Agarwal SS2, Rajagopalan K2, Rashid N1
1Dymaxium, Inc, Toronto, ON, Canada; 2Biogen Idec GmbH, Wellesley, MA, USA
OBJECTIVES: Multiple sclerosis (MS) is a chronic incurable disease with a progressive 
course. Studies have demonstrated that disease progression can be slowed by treatment 
with disease modifying therapies (DMTs). Poor DMT adherence is associated with a 
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higher risk of relapse, lower quality of life and higher medical costs. The adherence 
measure, persistency, refers to the duration a patient continues with therapy. This 
study aims to evaluate the non-pharmacy medical costs associated with the persistency 
of DMT’s in patients with MS. METHODS: A decision-analytic model was designed 
using persistency rates, health care resource use and costs from the published litera-
ture. The model evaluated the medical costs associated with the persistence, switching, 
and discontinuation rates of patients on interferon β1a IM, interferon β1b SC, and 
interferon β1a SC over a 2-year time horizon. Using 6-month intervals in the model, 
patients could switch to a comparator treatment, discontinue treatment, or persist/
remain on their current treatment, and would incur the non-pharmacy medical costs 
associated with each. For patients who switched treatments, the model assumed an 
equal probability of switching to the three remaining DMTs. The model also assumed 
that patients who discontinued therapy would initiate on a different therapy after one 
month of discontinuing. The overall medical costs related to persisting on treatment, 
switching treatment or discontinuing treatment were calculated for all treatment arms. 
RESULTS: Based on the results from the model, an annual per-patient medical cost 
of $7423 was observed for interferon β1a IM patients, showing a medical cost advan-
tage over patients on interferon β1b SC ($8144; 8.9%), and interferon β1a SC ($7552; 
1.7%). CONCLUSIONS: MS is a lifelong disease that requires continuous treatment. 
The results of this model show that interferon β1a IM is a cost-saving treatment for 
the medical costs associated with MS patients on disease modifying therapies.
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THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL 
SEALANT COMPARED WITH FIBRIN SEALANT TO PREVENT CEREBRAL 
SPINAL FLUID LEAKS AFTER CRANIAL SURGERY IN THE UK
Ott M1, Grieve J2, Larkin M3, Minshall M4
1Covidien, Zurich, Switzerland; 2University College London, London, UK; 3PRMA Consulting, 
Fleet, UK; 4Covidien, Fishers, IN, USA
OBJECTIVES: Cerebrospinal ﬂ uid (CSF) leak is an unavoidable consequence of 
cranial surgery with leak rates between 0% to 25% and resulting costs ranging from 
£9,000 to £36,000. The use of polyethylene glycol (PEG) hydrogel dural sealant as 
an adjunct to sutured closure has been shown to reduce CSF leak rates as compared 
with sutures alone in cranial procedures (GR Cosgrove et al, 2007). Our hypothetical 
analysis applied the potential cost offsets of using PEG hydrogel sealant as an adjunct 
to sutured closure in 200 cranial procedures assuming CSF leak rates of 4.5% (9/200) 
(GR Cosgrove et al, 2007), compared with 10% (20/200) for ﬁ brin sealant (JA Gro-
tenhuis, 2005). METHODS: The incremental additional cost for treating CSF leaks 
using total patient costs for those with CSF leaks (£25,253) compared to those without 
CSF leaks (£10,497) was estimated at £14,756 in a Dutch study (JA Grotenhuis, 
2005). We applied this CSF leak cost to estimate potential UK hospital cost offsets 
on 200 hypothetical cranial patients using PEG hydrogel sealant (£300/treatment), 
compared with ﬁ brin sealant (£133/treatment) on all 200 patients. RESULTS: Use of 
a PEG hydrogel sealant compared with ﬁ brin sealant could potentially save £137,611 
(or £688/patient) for a hospital that performed 200 cranial surgery procedures using 
a PEG hydrogel sealant compared with using ﬁ brin sealant on all 200 procedures. 
CONCLUSIONS: This study demonstrates the potential economic advantages of using 
a PEG hydrogel sealant in cranial procedures. Future clinical direct comparative 
studies would be beneﬁ cial to conﬁ rm these ﬁ ndings and understand the possible 
economic advantages for other types of dural surgeries.
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ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN 
HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY 
OF 100 PATIENTS
Érsek K1, Mikudina B1, Arányi Z2, Juhos V3, Baji P1, Péntek M1, Brodszky V1, Gulácsi L1
1Corvinus University of Budapest, Budapest, Hungary; 2Semmelweis University, Budapest, 
Hungary; 3St. István and St. László Hospital, Budapest, Hungary
OBJECTIVES: Epilepsy is the second most frequent neurological disease among 
adults; approximately 50–60 thousand people suffer from epilepsy in Hungary. With 
our survey we aimed to assess the cost of illness from a societal viewpoint as well as 
the quality of life associated with epilepsy in Hungary. METHODS: We conducted a 
cross-sectional questionnaire survey of 100 consecutive patients in 2 epilepsy centres 
in Hungary in collaboration with epilepsy specialists. The self-developed questionnaire 
consisted of general and disease-speciﬁ c parts to determine costs associated with 
epilepsy. Questions related to basic demographic characteristics, disease progression 
and health and social services used in the past 12 months, disease-associated non-
medical services, as well as the productivity losses of epilepsy. Two generic quality of 
life questionnaires, EQ-5D and SF-36 were also used. RESULTS: A total number of 
100 patients were assessed (60% female). The average age was 36.7 years (SD. 12.5), 
average disease duration was 15 years (SD. 12). Quality of life calculations resulted 
in mean of 0.83 (SD. 0.24) in EQ-5D, 74 (SD. 16) in VAS scale and 72.3 (SD. 20.2) 
in SF-36. Cost-of-illness calculations were carried out and direct (15%) and indirect 
costs (85%) were determined. The annual total cost of epilepsy per capita was esti-
mated to be a mean of c5179 (SD. c10,822) with the human resource method, while 
c2,552/capita/year (SD. 8659) by the friction cost method. CONCLUSIONS: Compar-
ing the 100 patients’ data with data from previous EQ-5D based population-sample 
survey shows that quality of life among people with epilepsy was lower than among 
the average Hungarian population. We found signiﬁ cant correlation (at P < 0.05) 
among all of the quality of life results and the yearly total costs (calculating both with 
human capital and friction cost methods).
PND10
LONG-TERM DISABILIY COST IN TUBEROUS SCLEROSIS COMPLEX 
(TSC) IN BRAZIL
Valentim J
Novartis, Sao Paulo, SP, Brazil
OBJECTIVES: To estimate long-term disability costs associated with tuberous sclero-
sis complex, a rare multisystem genetic disease, in Brazil. METHODS: Literature 
review for TSC long-term disability and economic burden was performed (Pubmed, 
LILACS, SciELO, CRDs). Cost estimation was limited to epilepsy (most prevalent TSC 
disorder). Cost of lost productivity in patients since epilepsy onset in childhood and 
carried in adulthood as well as caregivers’ productivity costs were estimated. The 
Human Capital Method was adopted and potential lost working years estimated till 
an active age of 65 years. It was assumed a caregiver for all ages. Average income, 
unemployment rate due to epilepsy, productivity growth and epidemiology data were 
obtained from the literature and from the Brazilian Institute of Geography and Sta-
tistics. Mean annual productivity cost per patient, total productivity cost per patient 
and the total productivity burden of TSC-related epilepsy were calculated. Costs were 
estimated in 2008 Reals and discounted at 5%. Univariate sensitivity analysis was 
conducted for epidemiology data, employment status rate, productivity growth, dis-
count rate and time horizon. RESULTS: Productivity loss was 47, 30 and 65 years 
for epilepsy onset in childhood and adulthood and caregivers, respectively. The dis-
counted and not discounted mean annual productivity cost per patient were R$1,970 
and R$11,323, total productivity cost per patient R$97,882 and R$691,150 and total 
productivity burden of TSC-related epilepsy in Brazil R$1,568,965,961 and 
R$11,078,536,271, respectively (1Euro = 3.24Reals). Results were sensitive to all the 
parameters varied in the sensitivity analysis, especially discount rate. CONCLU-
SIONS: TSC-related epilepsy is a chronic disorder associated with loss of productivity 
with a signiﬁ cant economic burden in Brazil. Although signiﬁ cant, the economic 
burden related to productivity loss is expected to be even higher since there are still 
costs deriving from absenteeism of patients and caregivers when employed looking for 
health services to be included in further analysis.
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NURSE COSTING SURVEY FOR THE MANAGEMENT OF ADVERSE 
EVENTS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH 
DISEASE-MODIFYING DRUGS IN THE UK
Perard R, Parkes L
1Merck Serono Limited, Feltham, UK
OBJECTIVES: To determine the costs and medical resource use for the management 
of injection-site reactions (ISRs) and ﬂ u-like symptoms (FLS) associated with injectable 
disease-modifying drugs (DMDs) used to treat patients with relapsing–remitting mul-
tiple sclerosis (RRMS) in the UK. METHODS: A survey was carried out amongst 
NHS nurses to understand the management of adverse events occurring with injectable 
DMD use. Data were collected via a postal questionnaire. Responses were compiled 
for the frequency and duration of side-effects, support received and medical consulta-
tions required for adverse event management. The unit costs were derived from the 
Personal Social Services Research Unit, the Ofﬁ ce for National Statistics and the British 
National Formulary. Once all parameters and unit prices were characterised with 
conservative approaches for missing data (e.g. no GP consultation mandatory before 
antibiotics prescription), computations were processed to determine means and stan-
dard deviations (SDs). RESULTS: In total, 19 NHS nurses managing signiﬁ cant 
numbers of patients with MS for different primary care trusts participated in the 
costing survey. On average, the nurses reported that patients experienced 27 ISRs per 
year of those 33% experienced ISRs only at treatment start while 21% experienced 
ISRs continuously during the year. Seventy-four percent experienced FLS only at 
treatment start and 11% continuously. The average cost for the management of ISRs 
per year was £187 (SD £209) equivalent to an average cost of £7 per event. The 
average cost for the management of FLS per year was £166 (SD £144) equivalent to 
an average cost of £6 per event. CONCLUSIONS: This is the ﬁ rst UK study to provide 
data on the costs associated with management of ISRs and FLS occurring with inject-
able DMDs. These data, alongside prevalence estimates, enabled us to calculate the 
costs of managing adverse events associated within DMDs in an economic model.
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EUROPEAN-HUNTINGTON’S DISEASE BURDEN STUDY (EURO-HDB)—
PRELIMINARY RESULTS FOR ITALY AND FRANCE
Dorey J1, Toumi M2, Clay E1, Tedroff J3, Squitieri F4, De Nicola N4, Verny C5
1Creativ Ceutical, Paris, France; 2University Claude Bernard Lyon 1, Lyon, France; 
3NEUROSEARCH, Ballerup, Denmark; 4Neurogenetics and Rare Disease Centre, Pozzilli, 
Italy; 5Neurology Unit CHU, Angers, France
OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease leading 
to sustained disability and poor health-related quality of life (HRQOL). As new treat-
ments are in development for HD, data on the burden of disease are required. This 
study evaluated patient health status, patient and caregiver HRQoL and costs in HD. 
METHODS: Euro-HDB is a European cross-sectional survey being conducted in eight 
European countries. Self-reported questionnaires were completed by patients and care-
givers. The patient questionnaire includes the Huntington Self-Assessment Instrument, 
a speciﬁ c tool that assesses clinical characteristics, HRQoL and health care resource 
utilization. The EQ5D questionnaire and the SF36 Survey are also included. RESULTS: 
To date, 201 patients have been enrolled in France and 124 in Italy. 
All levels of disease severity are represented. Average annual costs from societal 
